Cellectar Biosciences, Inc. (CLRB)

NASDAQ: CLRB · USD

$1.25

+0.04 (+3.3%)· Recorded snapshot

Market cap	11.8M
Net income (ttm)	-22.3M
EPS (ttm)	-$3.75
Shares out	9.5M
Volume	56,484
Beta	0.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -22.3M
EPS (ttm): -$3.75
Market cap: 11.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-119.6

P25 n/aP50 n/aP75 n/a

ROIC-74.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CLRB indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001279704
Company name	Cellectar Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	15117F880
Earnings date	2026-11-12
Earnings time	bmo
Employees	11
Employees change	-9
Employees growth	-45%
Enterprise value	$-20.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2002
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US15117F8804
Last 10-K release date	2026-03-04
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2025-06-24
Last stock split type	Reverse
Market cap	$11.8M
Market cap category	Nano-Cap
Next earnings date	2026-11-12
Options	No
Price	$1.25
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CLRB
U.S. state	New Jersey
Website	https://www.cellectar.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-300.1%
FCF / EV yield	93.71%
FCF yield	-166.95%
P/B ratio	0.33x
Price / tangible book value	0.39x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2M
ROA	-58.44%
ROA (5Y)	-96.15%
ROCE	-74.94%
ROE	-119.57%
ROIC	-74.8%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	3
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9,258
Depreciation and amortization	$172,786
EBIT	$-23.5M
EBITDA	$-23.4M
EPS	$-3.75
FCF per share	$-2.06
Financing cash flow	$42.4M
Free cash flow	$-19.5M
Free cash flow minus SBC	$-21.5M
Investing cash flow	$-9,258
Net cash flow	$23M
Net income	$-22.3M
Operating cash flow minus SBC	$-21.5M
Operating income	$-23.5M
Stock-based compensation	$2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$3.62
Debt / equity	0.05
Long-term assets	$1.8M
Long-term liabilities	$1.5M
Net cash (debt)	$32.5M
Net cash / market cap	278.16%
Net cash growth	206.61%
Net debt / equity	-1.09
Piotroski F-Score	2
Property, plant and equipment	$1.7M
Shareholders' equity	$29.9M
Tangible book value	$29.9M
Tangible book value per share	$3.62
Total assets	$36.6M
Total cash	$34M
Total debt	$1.5M
Total liabilities	$6.8M
WACC	6.56%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$34.9M
Current liabilities	$5.2M
Current ratio	6.66
Net working capital	$-4.4M
Quick ratio	6.49
Working capital	$29.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-306.49%
Dividend yield	0%
Shareholder yield	-306.49%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.98%
10Y return CAGR	-56.85%
10Y total return	-99.98%
150-day SMA	$2.46
15Y price change	-100%
15Y return CAGR	-57.78%
15Y total return	-100%
1D price change	3.31%
1M price change	-31.67%
1M total return	-31.67%
1Y price change	-65.74%
1Y return CAGR	-65.76%
1Y total return	-65.74%
20-day SMA	$1.36
200-day SMA	$2.66
3M price change	-49.17%
3M total return	-49.17%
3Y price change	-98.26%
3Y return CAGR	-74.06%
3Y total return	-98.26%
50-day SMA	$1.94
50-day SMA vs 200-day SMA	50under200
52-week high	$4.70
52-week high date	2026-05-05
52-week low	$1.12
52-week low date	2026-10-20
5Y price change	-99.52%
5Y return CAGR	-65.62%
5Y total return	-99.52%
6M price change	-52.87%
6M total return	-52.87%
All-time high	$1,799,964.00
All-time high date	2011-04-11
All-time low	$1.12
All-time low date	2026-10-16
Average true range (ATR)	$0.13
Average volume	170.6K
Beta (1Y)	1.76
Beta (2Y)	1.28
Beta (5Y)	0.58
Change from 52-week high	-73.4%
Change from 52-week low	11.61%
Change from all-time high	-100%
Change from all-time low	9.82%
Change from open	3.73%
Day's gap	-0.41%
Dollar volume	$70,605
High price	$1.26
Low price	$1.20
Monthly RSI	26.35
Open price	$1.21
Position in 52-week range	83.33%
Premarket change	2.48%
Premarket close	$1.21
Premarket price	$1.24
Previous close	$1.21
Price vs 150-day SMA	-50.06%
Price vs 20-day SMA	-9.56%
Price vs 200-day SMA	-53.76%
Price vs 50-day SMA	-36.63%
Relative volume	0.33
RSI	30.51
Sharpe ratio	-1.03
Sharpe ratio (3Y)	-0.8
Sharpe ratio (5Y)	-0.66
Sortino ratio	-1.37
Sortino ratio (3Y)	-1.02
Sortino ratio (5Y)	-0.87
Volume	56.5K
Weekly RSI	28.43
YTD price change	-58.31%
YTD total return	-58.31%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	9.3M
Float percentage	98.17%
Shares change (QoQ)	188.48%
Shares change (YoY)	306.49%
Shares held by insiders	1.83%
Shares held by institutions	40.88%
Shares outstanding	9.5M
Short % of float	2.84%
Short % of shares	2.79%
Short ratio	2.7 days

Deeper analysis on CLRB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CLRB report

Is a complete CLRB research report available?

No complete published report is available for Cellectar Biosciences, Inc. (CLRB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Cellectar Biosciences, Inc. (CLRB)

Price

Financial snapshot

Fair-value bridge

Latest news · CLRB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CLRB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CLRB

Frequently asked questions